Sort
48,018 grants matching “immunotherapy”
Regulation of Tumor Microenvironment in Cancer
$373,604Dmitry Isaac Gabrilovich · Wistar Institute · R01 · FY2015 · CA
Core 2
$373,592Kavita Dhodapkar · Emory University · P01 · FY2023 · CA
Preclinical and Clinical Studies of MUC1 Glycopeptide Vaccine Strategies in Breas
$373,582Sandra Jane Gendler · Mayo Clinic Rochester · P50 · FY2009 · CA
Sensitizing high grade serous cancers to immunotherapy through the induction of DNA damage
$373,561Karen McLean · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA
Duke Research Training Program in Surgical Oncology
$373,556David H Harpole · Duke University · T32 · FY2025 · CA
RP-1: Defining Predictors of Sensitivity to Cisplatin-Based Chemotherapy in Urothelial Cancer
$373,548David B. Solit · Sloan-Kettering Inst Can Research · P50 · FY2020 · CA
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
$373,547David E Fisher · Massachusetts General Hospital · R01 · FY2021 · CA
A druggable dependency in low-MITF/high-AXL melanoma: preclinical efficacy and mechanism of action in a key treatment-resistant subclass.
$373,547David E Fisher · Massachusetts General Hospital · R01 · FY2020 · CA
Deciphering the function of DNp63 and MDSCs in tumor promotion and metastasis of TNBCs
$373,520Rumela Chakrabarti · University Of Pennsylvania · R01 · FY2020 · CA
The Significance of MARCO Expression by Tumor-Pulsed Dendritic Cells
$373,500James J Mule · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2008 · CA
Virulence and Immunity to Staphylcocci
$373,476Brigham And Women'S Hospital · R01 · FY2002 · AI
Project 4: Interrogating and harnessing age-related IFN signaling and innate immunity in HCC prevention and therapy
$373,461Gen-Sheng Feng · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2021 · AG
Melanoma-associated retinopathy: detection and mechanisms
$373,450Catherine W Morgans · Oregon Health & Science University · R01 · FY2021 · EY
Extratumoral biological determinants that decrease survival in older adults with glioblastoma
$373,450Derek Alan Wainwright · Loyola University Chicago · R01 · FY2024 · NS
Melanoma-associated retinopathy: detection and mechanisms
$373,450Catherine W Morgans · Oregon Health & Science University · R01 · FY2022 · EY
Understanding Immunopathogenesis of Hepatitis B Virus
$373,430Jody L Baron · University Of California, San Francisco · R01 · FY2007 · AI
Gene Edited and Engineered Tumor Cell Therapeutics for Cancer
$373,424Khalid A Shah · Brigham And Women'S Hospital · R01 · FY2025 · NS
Targetable Immune Evasion Pathways in Hodgkin Lymphoma
$373,399Margaret A Shipp · Dana-Farber Cancer Inst · R01 · FY2020 · CA
Targetable Immune Evasion Pathways in Hodgkin Lymphoma
$373,399Margaret A Shipp · Dana-Farber Cancer Inst · R01 · FY2017 · CA
Developmental Funds
$373,395Ralph W. De Vere White · University Of California At Davis · P30 · FY2016 · CA
Regulation of Macrophage- and Microglia-mediated STING Signaling in Glioblastoma
$373,358Rongze Olivia Lu · University Of California, San Francisco · R01 · FY2024 · NS
Signature-guided therapy for mismatch repair defective cancers
$373,331Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Signature-guided therapy for mismatch repair defective cancers
$373,331Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2020 · CA
Signature-guided therapy for mismatch repair defective cancers
$373,331Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2018 · CA
Signature-guided therapy for mismatch repair defective cancers
$373,331Shiaw-Yih Lin · University Of Tx Md Anderson Can Ctr · R01 · FY2017 · CA